ERBB2 and breast carcinoma: However, an overview of the ypN+ rate in this population for different breast cancer subtypes is lacking.<h4>Objective</h4>To provide the pooled ypN+ rate in cN0 patients who achieved bpCR after NST in different breast cancer subtypes defined by hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status.<h4>Methods</h4>A systematic literature search was conducted in Embase and PubMed on July 20, 2022.